Tags Archive Navigation
icon
-
Media ReleaseNovartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
-
Media ReleaseNovartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
-
Media ReleaseNovartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
-
Media ReleaseNovartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
-
Media ReleaseNovartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
-
Media ReleaseUp to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
-
Media ReleaseApproximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
-
Media ReleaseFDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media ReleaseNovartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-
Media ReleasePatients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
-
Media ReleaseNovartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 50
- › Next page